Evangelia Argyriou1, Noemin Kapsala2, Konstantinos Thomas3, Alexandros Panagiotopoulos3, Aglaia Chalkia4, Emilia Hadziyannis3, Kyriaki Boki1, Pelagia Katsimbri2, Dimitrios T Boumpas2, Panagiota Giannou4, Dimitrios Petras4, Dimitrios Vassilopoulos5. 1. Rheumatology Unit, Sismanoglio General Hospital, Athens, Greece. 2. Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 4th Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece. 3. Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens School of Medicine, Hippokration General Hospital, 114 Vass. Sophias Ave, 115 27, Athens, Greece. 4. Nephrology Department, Hippokration General Hospital, Athens, Greece. 5. Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens School of Medicine, Hippokration General Hospital, 114 Vass. Sophias Ave, 115 27, Athens, Greece. dvassilop@med.uoa.gr.
Abstract
BACKGROUND: Serious infections (SI) are common in patients with ANCA-associated vasculitides (AAV) like granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Real-life data regarding their incidence and predisposing factors-after the introduction of B cell depleting agents-are limited while data quantifying the risk per treatment modality and year of the disease are missing. Here, we aim to describe in details the incidence and the risk factors for SI in a contemporary AAV cohort. METHODS: Multicenter, observational, retrospective study of AAV patients followed in three tertiary referral centers. RESULTS: We included 162 patients with GPA (63%) and MPA (37%), males 51.9%, mean age 60.9 years, ΑΝCA+ 86%, and generalized disease 80%. During follow-up (891.2 patient-years, mean 5.4 years), 67 SI were recorded in 50 patients at an incidence rate of 7.5 per 100 patient-years. The SI incidence rate was higher during induction with cyclophosphamide (CYC) compared to rituximab (RTX, 19.3 vs. 11.3 per 100 patient-years, respectively) while it was lower and comparable between RTX and other regimens (5.52 vs. 4.54 per 100 patient-years, respectively) in the maintenance phase. By multivariate analysis, plasmapheresis (PLEX) and/or dialysis was a strong predictor for an SI during the 1st year after diagnosis (OR = 3.16, 95% CI 1.001-9.96) and throughout the follow-up period (OR = 5.21, 95% CI 1.93-14.07). In contrast, a higher baseline BVAS (OR = 1.11, 95% CI 1.01-1.21) was associated with SI only during the 1st year. CONCLUSIONS: In this real-life study of patients with AAV, the SI incidence was higher during CYC compared to RTX induction while there was no difference between RTX and other agents used for maintenance therapy. Higher disease activity at baseline and need for PLEX and/or dialysis were independent factors associated with an SI.
BACKGROUND: Serious infections (SI) are common in patients with ANCA-associated vasculitides (AAV) like granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Real-life data regarding their incidence and predisposing factors-after the introduction of B cell depleting agents-are limited while data quantifying the risk per treatment modality and year of the disease are missing. Here, we aim to describe in details the incidence and the risk factors for SI in a contemporary AAV cohort. METHODS: Multicenter, observational, retrospective study of AAV patients followed in three tertiary referral centers. RESULTS: We included 162 patients with GPA (63%) and MPA (37%), males 51.9%, mean age 60.9 years, ΑΝCA+ 86%, and generalized disease 80%. During follow-up (891.2 patient-years, mean 5.4 years), 67 SI were recorded in 50 patients at an incidence rate of 7.5 per 100 patient-years. The SI incidence rate was higher during induction with cyclophosphamide (CYC) compared to rituximab (RTX, 19.3 vs. 11.3 per 100 patient-years, respectively) while it was lower and comparable between RTX and other regimens (5.52 vs. 4.54 per 100 patient-years, respectively) in the maintenance phase. By multivariate analysis, plasmapheresis (PLEX) and/or dialysis was a strong predictor for an SI during the 1st year after diagnosis (OR = 3.16, 95% CI 1.001-9.96) and throughout the follow-up period (OR = 5.21, 95% CI 1.93-14.07). In contrast, a higher baseline BVAS (OR = 1.11, 95% CI 1.01-1.21) was associated with SI only during the 1st year. CONCLUSIONS: In this real-life study of patients with AAV, the SI incidence was higher during CYC compared to RTX induction while there was no difference between RTX and other agents used for maintenance therapy. Higher disease activity at baseline and need for PLEX and/or dialysis were independent factors associated with an SI.
Authors: Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne Journal: N Engl J Med Date: 2010-07-15 Impact factor: 91.245
Authors: Michael Walsh; Peter A Merkel; Chen-Au Peh; Wladimir M Szpirt; Xavier Puéchal; Shouichi Fujimoto; Carmel M Hawley; Nader Khalidi; Oliver Floßmann; Ron Wald; Louis P Girard; Adeera Levin; Gina Gregorini; Lorraine Harper; William F Clark; Christian Pagnoux; Ulrich Specks; Lucy Smyth; Vladimir Tesar; Toshiko Ito-Ihara; Janak Rashme de Zoysa; Wojciech Szczeklik; Luis Felipe Flores-Suárez; Simon Carette; Loïc Guillevin; Charles D Pusey; Alina L Casian; Biljana Brezina; Andrea Mazzetti; Carol A McAlear; Elizabeth Broadhurst; Donna Reidlinger; Samir Mehta; Natalie Ives; David R W Jayne Journal: N Engl J Med Date: 2020-02-13 Impact factor: 91.245
Authors: Pierre Charles; Élodie Perrodeau; Maxime Samson; Bernard Bonnotte; Antoine Néel; Christian Agard; Antoine Huart; Alexandre Karras; François Lifermann; Pascal Godmer; Pascal Cohen; Catherine Hanrotel-Saliou; Nicolas Martin-Silva; Grégory Pugnet; François Maurier; Jean Sibilia; Pierre-Louis Carron; Pierre Gobert; Nadine Meaux-Ruault; Thomas Le Gallou; Stéphane Vinzio; Jean-François Viallard; Eric Hachulla; Christine Vinter; Xavier Puéchal; Benjamin Terrier; Philippe Ravaud; Luc Mouthon; Loïc Guillevin Journal: Ann Intern Med Date: 2020-06-02 Impact factor: 25.391
Authors: Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon Journal: N Engl J Med Date: 2014-11-06 Impact factor: 91.245
Authors: Christian Pagnoux; Thomas Quéméneur; Jacques Ninet; Elisabeth Diot; Xavier Kyndt; Benoît de Wazières; Jean-Luc Reny; Xavier Puéchal; Pierre-Yves le Berruyer; Olivier Lidove; Philippe Vanhille; Pascal Godmer; Olivier Fain; Daniel Blockmans; Boris Bienvenu; Florence Rollot; Séverine Aït el Ghaz-Poignant; Alfred Mahr; Pascal Cohen; Luc Mouthon; Elodie Perrodeau; Philippe Ravaud; Loïc Guillevin Journal: Arthritis Rheumatol Date: 2015-04 Impact factor: 10.995
Authors: Aladdin J Mohammad; Mårten Segelmark; Rona Smith; Martin Englund; Jan-Åke Nilsson; Kerstin Westman; Peter A Merkel; David R W Jayne Journal: J Rheumatol Date: 2017-08-01 Impact factor: 4.666
Authors: Joanna Robson; Helen Doll; Ravi Suppiah; Oliver Flossmann; Lorraine Harper; Peter Höglund; David Jayne; Alfred Mahr; Kerstin Westman; Raashid Luqmani Journal: Ann Rheum Dis Date: 2013-11-15 Impact factor: 19.103
Authors: M Yates; R A Watts; I M Bajema; M C Cid; B Crestani; T Hauser; B Hellmich; J U Holle; M Laudien; M A Little; R A Luqmani; A Mahr; P A Merkel; J Mills; J Mooney; M Segelmark; V Tesar; K Westman; A Vaglio; N Yalçındağ; D R Jayne; C Mukhtyar Journal: Ann Rheum Dis Date: 2016-06-23 Impact factor: 27.973